CSIMarket
 


Antriabio, Inc.  (FMYY)
Other Ticker:  
 

Antriabio's Working Capital Ratio

FMYY's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Antriabio's Current Assets grew by 938.9 % in the sequentially, while Current Liabilities decreased, this led to improvement in Antriabio's Working Capital Ratio to 2.09 a new company high.

Within Major Pharmaceutical Preparations industry 211 other companies have achieved higher Working Capital Ratio than Antriabio in . While Working Capital Ratio total ranking has improved so far during the to 2121, from total ranking in the at 2449.

Explain Working Capital Ratio
How much in Current Assets FMYY´s has?
What is the value of FMYY´s Current Liabilities?


FMYY Working Capital Ratio (Mar 31 2014)
(Sep 30 2013)
(Jun 30 2013)


Y / Y Current Liabilities Change - - - - -
Y / Y Current Assets Change - - - - -
Working Capital Ratio MRQ 2.09 0.1 0.15 - -
FMYY's Total Ranking # 2121 # 2449 # 2449 # #
Seq. Current Liabilities Change -49.61 % 7.86 % - - -
Seq. Current Assets Change 938.9 % -29.37 % - - -



Working Capital Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 212
Healthcare Sector # 427
Overall Market # 2121


Working Capital Ratio Statistics
High Average Low
2.09 0.78 0.1
(Mar 31 2014)   (Sep 30 2013)




Financial Statements
Antriabio's Current Liabilities $ 3 Millions Visit FMYY's Balance sheet
Antriabio's Current Assets $ 6 Millions Visit FMYY's Balance sheet
Source of FMYY's Sales Visit FMYY's Sales by Geography


Cumulative Antriabio's Working Capital Ratio

FMYY's Working Capital Ratio for the trailling 12 Months

FMYY Working Capital Ratio

(Mar 31 2014)
(Sep 30 2013)
(Jun 30 2013)


Y / Y Current Liabilities TTM Growth - - - - -
Y / Y Current Assets TTM Growth - - - - -
Working Capital Ratio TTM 0.53 0.13 0.15 - -
Total Ranking TTM # 1222 # 0 # 0 # #
Seq. Current Liabilities TTM Growth -49.61 % 7.86 % - - -
Seq. Current Assets TTM Growth 938.9 % -29.37 % - - -


On the trailing twelve months basis FMYY Current Assets more than doubled by 938.9 % in year on year, faster than Current Liabilities, this led to increase in in Antriabio's Working Capital Ratio to 0.53, Working Capital Ratio remained below FMYY average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 211 other companies have achieved higher Working Capital Ratio than Antriabio. While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the from 0 to 1222.

Explain Working Capital Ratio
How much in Current Assets FMYY´s has?
What is the value of FMYY´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 212
Healthcare Sector # 427
Within the Market # 1222


trailing twelve months Working Capital Ratio Statistics
High Average Low
2.09 0.78 0.1
(Mar 31 2014)   (Sep 30 2013)




Companies with similar Working Capital Ratio in the quarter ending Mar 31 2014, within Major Pharmaceutical Preparations Industry Working Capital RatioMar 31 2014 MRQ Current AssetsMar 31 2014 MRQ Current Liabilities
Alexion Pharmaceuticals Inc   5.66 $ 2,245.880  Millions$ 396.822  Millions
Enveric Biosciences Inc   5.56 $ 0.027  Millions$ 0.005  Millions
Protalex Inc  5.48 $ 2.784  Millions$ 0.508  Millions
Insmed Inc  5.31 $ 106.209  Millions$ 19.998  Millions
Caladrius Biosciences Inc   5.30 $ 46.556  Millions$ 8.786  Millions
Omeros Corp  5.29 $ 54.132  Millions$ 10.232  Millions
Chembio Diagnostics Inc   5.26 $ 17.180  Millions$ 3.269  Millions
Agios Pharmaceuticals Inc   5.06 $ 172.417  Millions$ 34.081  Millions
Xoma Corporation  4.97 $ 100.572  Millions$ 20.253  Millions
Durect Corp  4.82 $ 25.490  Millions$ 5.285  Millions
Phibro Animal Health Corporation  4.81 $ 292.647  Millions$ 60.824  Millions
Stemline Therapeutics Inc  4.75 $ 26.003  Millions$ 5.473  Millions
Ibio inc   4.56 $ 5.532  Millions$ 1.213  Millions
Vbi Vaccines Inc  4.54 $ 16.271  Millions$ 3.582  Millions
Emergent Biosolutions Inc   4.52 $ 327.203  Millions$ 72.324  Millions
Allergan plc  4.37 $ 5,458.700  Millions$ 1,248.100  Millions
Cytokinetics Incorporated  4.35 $ 86.054  Millions$ 19.792  Millions
Xenetic Biosciences Inc   4.26 $ 11.499  Millions$ 2.700  Millions
Taro Pharmaceutical Industries Ltd  4.15 $ 1,051.271  Millions$ 253.304  Millions
Arena Pharmaceuticals Inc   4.13 $ 276.368  Millions$ 66.966  Millions
Sophiris Bio Inc.  4.09 $ 44.211  Millions$ 10.799  Millions
Corcept Therapeutics Inc  4.06 $ 48.120  Millions$ 11.862  Millions
Neubase Therapeutics inc   4.06 $ 3.711  Millions$ 0.915  Millions
Revance Therapeutics Inc   4.03 $ 91.172  Millions$ 22.609  Millions
Panbela Therapeutics Inc   3.91 $ 0.424  Millions$ 0.109  Millions
Cerevel Therapeutics Holdings Inc   3.88 $ 20.412  Millions$ 5.264  Millions
Avid Bioservices Inc   3.86 $ 85.771  Millions$ 22.207  Millions
Nektar Therapeutics  3.84 $ 304.770  Millions$ 79.313  Millions
Vertex Pharmaceuticals Inc  3.83 $ 1,430.330  Millions$ 373.500  Millions
Medicines Co  3.80 $ 595.688  Millions$ 156.760  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com